Chairman S. C. Ho

Born in Tainan City, Taiwan. Graduated from the Department of Mechanical Engineering of the National Cheng Kung University. Obtained an MS degree in Engineering Mechanics from the University of Wisconsin in the USA.

Mr Ho Show-Chung, Chairman of the SinoPac Holdings, is the first term President of the TRPMA, which consists of 25 member companies.   

Mr Ho expressed that after a decade of preparation, the industry has built up its capacity of new drug R&D.  The TRPMA’s top priority is to promote cross-strait cooperation in healthcare and to be involved in the Cross-Strait Cooperation Agreement.

Mr Ho also suggested that the DOH should work out a formula for pricing new drugs developed in Taiwan.  “The formula will reflect the government’s support for the bio-pharmaceutical industry in Taiwan,” said Mr Ho.  The TRPMA is co-founded by major local pharmaceutical manufacturers, including TTY, OEP, Sinphar and Synmosa, with joint effort from key bio-pharmaceutical developers, including TaiGen, PharmaEngine, TLC and OBI, as well as support from YFY Biotech Investment Co.

Build a Green Passage across the Strait

The TRPMA’s missions are to create a platform for the bio-pharmaceutical industry, to support the NHI and pharmaceutical affairs, to promote the development of the bio-pharmaceutical industry and cross-strait cooperation, and to become the industry’s point of contact to facilitate global R&D cooperation projects. 

Mr Ho, the President of the TRPMA, pointed out that the TRPMA is established mainly to support the negotiation of cross-strait health agreement, for example, to promote the cooperation between the TFDA and the SFDA.

Mr Ho said: “The Conference on Cross-strait Cooperation held in December 2012 indicates a new era of cross-strait cooperation.  In order to compete with Chinese manufacturers, manufacturers in Taiwan have to collaborate on research projects by pooling funds, technology and human resources together.”

Mr Ho also suggested that the government should fully support new drug R&D activities in Taiwan and establish an NHI drug pricing formula especially for new drugs choosing Taiwan as the first market for their global product launch.  The NHI system in Taiwan is known for its low price policy.  “Such price level is not possible to sustain the new drug industry in Taiwan.  The government should reflect its support for the new drug industry in its NHI new drug pricing policy,” said Mr Ho.



籲訂新藥健保藥價
理事長說:「但這樣的藥價,不一定能支撐台灣新藥產業的發展,所以新藥健保藥價的訂定,關係到政府支不支持新藥產業發展。」
陳志明說:「全球新藥藥價訂定可分2種,一是美國模式,也就是由廠商提一個價格,看各保險公司買不買帳,有利新藥廠商;另一類似台灣或歐洲,政府會有一審核藥價機制,審核參考著重在該藥品的社會成本,不同的訂價策略,就會牽動新藥廠商投入高成本研發新藥的企圖。」。

【台灣研發生技新藥發展協會小檔案】
首屆理事長:何壽川
成立宗旨:作為台灣生技新藥研發推動平台與對外窗口
首要任務:
◎協助兩岸藥政主管機關台灣食品藥物管理局(TFDA)與中國藥監局(SFDA)合作
◎聚焦華人共同的疾病,放眼整個國際市場
會員成員:東洋(4105)、友華(4120)、健喬信元(4114)、台灣浩鼎等25家國內新藥研發公司。